Monteplase
Alternative Names: Cleactor; E 6010Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator ZymoGenetics
- Developer Eisai; Eisai Co Ltd
- Class Plasminogen activator enzymes; Thrombolytics
- Mechanism of Action Plasminogen activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Embolism; Myocardial infarction; Thrombosis
- Discontinued Stroke
Most Recent Events
- 12 Oct 2010 ZymoGenetics has been acquired by Bristol-Myers Squibb
- 02 Aug 2005 Launched for Embolism in Japan (Injection)
- 29 Jul 2005 Discontinued - Phase-II for Stroke in Japan (Injection)